We conducted a study to assess trends in haemoglobin recovery among HIV-infected patients initiated on zidovudinebased combination antiretroviral therapy (cART) stratified by baseline haemoglobin level. Haemoglobin data from nonpregnant adult patients initiating cART in rural north-central Nigeria between June 2009 and May 2011 were analysed using a linear mixed effects model to assess the interaction between time, zidovudine-containing regimen and baseline haemoglobin level on the outcome of subsequent haemoglobin level. Best-fit curves were created for baseline haemoglobin in the 10th, 25th, 75th and 90th percentiles. We included 313 patients with 736 measures of haemoglobin in the analysis (239 on zidovudine and 74 on non-zidovudine-containing regimens). Median haemoglobin increased over time in both groups, with differences in haemoglobin response over time related to baseline haemoglobin levels and zidovudine use (p ¼ 0.003). The groups of patients on zidovudine at the 10th and 90th percentiles had downward sloping curves while all other groups had upward trending haemoglobin levels. Although haemoglobin levels increased overall for patients on zidovudine-containing regimens, for those in the 10th and 90th percentiles haemoglobin levels trended downward over time. These results have implications for decisions regarding when to initiate, switch from or avoid the use of zidovudine.
Background
Current World Health Organization (WHO) guidelines recommend zidovudine (ZDV)-based antiretroviral therapy (ART) as an affordable first-line treatment for HIV-infected patients in resource-limited settings, replacing stavudine-based regimens to reduce longterm toxicity. 1 ZDV (also called AZT for its first name azidothymidine) is a known cause of haematologic toxicities, particularly anaemia. 2 Because of this, the WHO guidelines recommend not prescribing ZDV to patients having baseline haemoglobin levels less than 7 g/dL. 1 The impact of ZDV-associated anaemia is variable in different settings. Although studies of HIV-infected patients in higher resourced settings have demonstrated recovery of haemoglobin levels after an initial decrease and overall improvement of baseline anaemia in patients treated with ZDV-based regimens, 3, 4 data from resource-limited settings show mixed results related to ZDV risk. In a Ugandan cohort, starting a ZDV-based regimen was not associated with increased risk of early severe anaemia. 5 However, a secondary analysis of a clinical trial and a multicenter cohort study including sites in Sub-Saharan Africa, Asia-Pacific and Latin America found associations between initial therapy containing ZDV and anaemia. 6, 7 Variability in findings is expected given that the studies had different structures and outcomes, with some analysing incident anaemia in patients with normal haemoglobin and others looking at changes in haemoglobin levels among anemic patients initiating ZDV-based regimens.
For front-line treatment implementation, it would be useful to know expected haemoglobin responses to ZDV at varying baseline haemoglobin levels, especially in the context of settings with high baseline levels of anaemia with multiple underlying causes (e.g. nutritional, AIDS-related, malaria or helminth-associated). [8] [9] [10] Nigeria is such a setting, with holoendemic malaria in much of the country, a significant burden of helminth infections, and nutritional deficiencies secondary to poverty. [11] [12] [13] Though ZDV is part of the recommended first-line regimen, Nigerian ART guidelines recommend avoiding the use of ZDV or switching to another drug in persons having baseline haemoglobin values of less than 8 g/dL. 14 CD4þ cells/mL, WHO stage III disease with <350 CD4þ cells/mL or WHO stage IV regardless of CD4 þ cell count. From June 2010 onward, patients having CD4 þ counts <350 or WHO stage III or IV regardless of CD4 þ cell count were eligible to initiate cART. ZDV-based regimens are used most commonly at the sites; alternate first-line regimens use tenofovir, abacavir or stavudine as the primary nucleoside analogue.
We used routinely collected PEPFAR programme data for this analysis. After each clinic day, FGH data clerks entered data from national patient management and monitoring (PMM) forms that had been completed by clinicians, nurses, laboratory and pharmacy staff into CAREWare TM (jProg Õ , New Orleans, LA). Routine audits of medical records were performed to ensure that forms were completed accurately and laboratory data were entered correctly. Data queries were generated for out-of-range and missing data. Each site addressed its data queries; clean data were extracted for the final analyses. All patients 15 years of age and older initiating cART between 9 June 2009 and 25 May 2011 who had at least two documented haemoglobin levels were eligible for analysis. Pregnant patients were excluded. Our main outcome was trends in haemoglobin values in HIV-infected patients on ZDV-based regimens, stratified by baseline haemoglobin level.
A linear mixed effects model was used to assess the interaction between time, ZDV-containing regimen and baseline haemoglobin level (within 90 days of cART initiation) on the outcome of subsequent haemoglobin level while adjusting for gender and cotrimoxazole use. 15 To account for non-linearity, baseline haemoglobin and time were transformed using natural cubic splines with three knots. 16 Best fit curves depicting trajectories of haemoglobin were created for four strata of baseline haemoglobin: the 10th, 25th, 75th and 90th percentiles. If patients were switched off ZDV, haemoglobin data were censored after the switch. Patients who died or were lost to follow-up contributed time until their last clinic visit. Patient demographics and clinical characteristics were compared by initial regimen using Wilcoxon rank-sum and chi-squared tests, as appropriate. We employed R software 2. 15 
Results
We identified 313 patients with 736 measures of haemoglobin who met inclusion criteria with 239 on ZDVbased initial regimens and 74 on non-ZDV regimens. The median age of patients was 34 years and 67% were female. There were no statistically significant differences between the ZDV and non-ZDV groups in either demographic profiles or baseline CD4 count ( Table 1 ). Body mass index was very slightly higher in the ZDV group (20.5 versus 20.1; p ¼ 0.03). Baseline haemoglobin levels were higher for patients initiated on ZDV-based cART (median 10.4 g/dL versus 9.9 g/dL, p < 0.001). There were 55 patients who were lost to follow-up and 11 patients who died during the first year on treatment, with no significant differences between the groups.
There was an increase in median haemoglobin response over one year both for patients on ZDV (þ1.8 g/dL) and for patients not on ZDV (þ0.7 g/dL), with overlapping confidence intervals (Figure 1 ). After an initial increase, the group of patients on ZDV at the lowest baseline haemoglobin level (the 10th percentile at 7.7 g/dL) had a downward sloping curve starting at about 150 days on therapy. Patients on ZDV with initial haemoglobin levels at the 90th percentile (13.0 g/ dL) also had a downward trajectory for haemoglobin, with estimated expected levels of 10.4 g/dL at 365 days. All other curves for both ZDV-based regimens and non-ZDV-based regimens had upward trending haemoglobin responses (Figure 2 ). There was evidence of differences in haemoglobin response over time related to baseline haemoglobin levels and ZDV use (three-way interaction, p ¼ 0.003). Figure 3 depicts the relationship between baseline and 365-day haemoglobin, illustrating the lower year-end values at both ends of the baseline haemoglobin spectrum for patients receiving ZDV-based cART.
Discussion
In the context of all that is known about the effect of ZDV on haemoglobin, this study sheds light on the relationship between the haemoglobin level at cART initiation and the changes in haemoglobin over time in real-world rural settings. For patients initiated on ZDV-based regimens, we found that though haemoglobin levels increased overall, for those in the 10th and 90th percentiles, haemoglobin levels trended downward over time. Patients starting ART at the lower end of haemoglobin values may well be sicker than other patients such that co-infections or nutritional disadvantages are extant. Our findings are consistent with a prior study in West Africa that found associations between the risk of grade 3 and 4 anaemia with low baseline haemoglobin levels. 17 For the patients starting ART at the highest levels of haemoglobin, a regression to the mean phenomenon is likely. In addition, clinicians may not be as concerned about ZDV-related decreases in haemoglobin, feeling that these patients have a larger buffer zone before a switch from ZDV may be indicated.
A strength of our study is its likely overall representativeness to many other African PEPFAR-supported initiatives, as it reflects real-world challenges in rural settings. Limitations of our study included the lack of data in our database on the use of blood transfusions for patients with severe anaemia. The use of such a procedure would move findings in the lowest haemoglobin percentile group toward the null; however, our data show declining haemoglobin trends in this group. The modest sample size and predominantly female study population could limit generalisability of findings. Similar studies are warranted in other patient populations. In addition, we examined only two haemoglobin data points in some patients, which may not be sufficient to reliably ascertain trends. We did not assess medication intake using validated measures of adherence, such as pill count or MEMS bottles; nor did we have data on specific factors or comorbidities that may contribute to anaemia. However, we think it likely that differences in adherence and the distribution of anaemia-related factors between ZDV and non-ZDV groups will be non-differential.
In conclusion, when ZDV-based regimens are used in settings where anaemia is prevalent, one can have an expectation of improvement in haemoglobin levels over time, with the exception of those initiating cART in the lowest haemoglobin percentile ( 7.7 g/dL in our study), and less critically, in persons with the highest haemoglobin levels. Our findings can influence clinical decisions regarding at which levels of haemoglobin to start ZDV-based regimens, when to switch from ZDV and when to avoid ZDV altogether.
